SG Americas Securities LLC Cuts Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)
SG Americas Securities LLC Cuts Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)
SG Americas Securities LLC trimmed its position in shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) by 42.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,618 shares of the company's stock after selling 13,481 shares during the quarter. SG Americas Securities LLC's holdings in Replimune Group were worth $322,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
根据SG America Securities LLC最近提交给美国证券交易委员会(SEC)的文件，该公司第三季度将其在Replimune Group，Inc.(纳斯达克代码：REPL-GET Rating)的股票头寸削减了42.0%。该基金在本季度出售了13,481股后，持有18,618股该公司股票。截至最近向美国证券交易委员会(Securities and Exchange Commission，美国证券交易委员会)提交的文件，SG America Securities LLC持有的Replimune Group股份价值322,000美元。
A number of other hedge funds have also recently bought and sold shares of the company. Harbor Capital Advisors Inc. boosted its holdings in shares of Replimune Group by 1.7% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 30,695 shares of the company's stock worth $537,000 after buying an additional 513 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Replimune Group by 6.7% in the 2nd quarter. Legal & General Group Plc now owns 8,324 shares of the company's stock worth $146,000 after buying an additional 526 shares during the last quarter. Virtus ETF Advisers LLC boosted its holdings in shares of Replimune Group by 25.9% in the 2nd quarter. Virtus ETF Advisers LLC now owns 7,108 shares of the company's stock worth $124,000 after buying an additional 1,461 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Replimune Group by 5.2% in the 1st quarter. Rhumbline Advisers now owns 32,643 shares of the company's stock worth $554,000 after buying an additional 1,616 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Replimune Group by 8.2% in the 1st quarter. Swiss National Bank now owns 49,900 shares of the company's stock worth $847,000 after buying an additional 3,800 shares during the last quarter. 87.83% of the stock is owned by hedge funds and other institutional investors.
其他一些对冲基金最近也买卖了该公司的股票。港湾资本顾问公司在第二季度增持了1.7%的Replimune Group股票。Harbor Capital Advisors Inc.现在持有30,695股该公司股票，价值537,000美元，在上个季度又购买了513股。Legal&General Group Plc在第二季度增持了Replimune Group 6.7%的股票。Legal&General Group Plc现在持有该公司8,324股股票，价值14.6万美元，上个季度又购买了526股。Virtus ETF Advisers LLC在第二季度将其持有的Replimune Group股票增加了25.9%。Virtus ETF Advisers LLC现在持有该公司7,108股股票，价值12.4万美元，上个季度又购买了1,461股。Rhumbline Advisers在第一季度将其在Replimune Group的股票持有量增加了5.2%。Rhumbline Advisers现在拥有该公司32,643股股票，价值554,000美元，在上个季度又购买了1,616股。最后，瑞士国家银行在第一季度增持了Replimune Group的股票8.2%。瑞士国家银行在上个季度又购买了3,800股后，现在持有49,900股该公司股票，价值847,000美元。87.83%的股票由对冲基金和其他机构投资者持有。
Insider Activity
内幕活动
In other news, insider Pamela Esposito sold 15,000 shares of the company's stock in a transaction dated Friday, December 9th. The stock was sold at an average price of $25.03, for a total transaction of $375,450.00. Following the sale, the insider now directly owns 229,402 shares in the company, valued at $5,741,932.06. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 23.80% of the company's stock.
在其他新闻方面，内部人士帕梅拉·埃斯波西托在12月9日星期五的交易中出售了15,000股该公司股票。该股以25.03美元的平均价格出售，总成交金额为375,450.00美元。出售后，这位内部人士现在直接拥有该公司229,402股，价值5741,932.06美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在这个环节。公司内部人士持有该公司23.80%的股份。
Replimune Group Trading Down 0.9 %
Replimune Group股价下跌0.9%
Replimune Group (NASDAQ:REPL – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.01). On average, equities analysts forecast that Replimune Group, Inc. will post -2.99 EPS for the current fiscal year.
复制集团(纳斯达克代码：REPL-GET Rating)上一次公布季度收益是在11月3日星期四。该公司公布了本季度每股收益(0.79美元)，低于普遍预期的(0.78美元)和(0.01美元)。股票分析师平均预测Replimune Group，Inc.本财年每股收益将为2.99欧元。
Analysts Set New Price Targets
分析师设定新的价格目标
A number of brokerages recently weighed in on REPL. SVB Leerink boosted their price target on shares of Replimune Group from $30.00 to $34.00 and gave the stock an "outperform" rating in a report on Wednesday, December 7th. HC Wainwright lowered their price objective on Replimune Group from $60.00 to $48.00 and set a "buy" rating on the stock in a research note on Friday, November 4th. Piper Sandler boosted their price objective on Replimune Group from $43.00 to $58.00 in a research note on Wednesday, December 14th. EF Hutton Acquisition Co. I began coverage on Replimune Group in a research note on Thursday, January 5th. They issued a "buy" rating and a $60.00 price objective on the stock. Finally, BMO Capital Markets boosted their price objective on Replimune Group from $40.00 to $70.00 and gave the company an "outperform" rating in a research note on Monday, December 12th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $51.57.
一些券商最近也加入了REPL的行列。SVB Leerink将Replimune Group的股票目标价从30.00美元上调至34.00美元，并在12月7日(周三)的一份报告中给出了该股“跑赢大盘”的评级。11月4日，在一份周五的研究报告中，HC Wainwright将Replimune Group的目标价从60.00美元下调至48.00美元，并对该股设定了“买入”评级。派珀·桑德勒在12月14日星期三的一份研究报告中将Replimune Group的目标价从43.00美元上调至58.00美元。EF Hutton Acquisition Co.I在1月5日星期四的一份研究报告中开始对Replimune Group进行报道。他们对该股给予“买入”评级和60.00美元的目标价。最后，蒙特利尔银行资本市场将Replimune Group的目标价从40.00美元上调至70.00美元，并在12月12日(星期一)的一份研究报告中给出了该公司“跑赢大盘”的评级。根据MarketBeat.com的数据，七位股票研究分析师对该股的评级为买入，该公司的普遍评级为买入，平均目标价为51.57美元。
About Replimune Group
关于复制组
(Get Rating)
(获取评级)
Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.
Replimune Group，Inc.是一家生物技术公司，开发治疗癌症的溶瘤免疫基因疗法。它使用其专有的免疫疗法平台来设计和开发旨在激活免疫系统对抗癌症的候选产品。该公司的主要候选产品是RP1，这是单纯疱疹病毒1型的选择性复制版本，目前正处于针对一系列实体肿瘤的I/II期临床试验，以及针对皮肤鳞状细胞癌患者的II期临床试验。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Replimune Group (REPL)
- Is Seagate Technology Signaling the End of its Normalization?
- eHealth Stock Rises from the Ashes. Time to Get In?
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- 免费获取StockNews.com关于Replimune Group的研究报告(REPL)
- 希捷科技是否在暗示其正常化的结束？
- EHealth股票从灰烬中崛起。是时候上车了吗？
- Yext AI搜索平台能否推动2023年的增长？
- 木薯科学公司的股票以124美元的目标价被低估了？
- 星座品牌：消费者正在降低购买铁路饮料的价格吗？
Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL – Get Rating).
想看看其他对冲基金持有REPL吗？访问HoldingsChannel.com获取Replimune Group，Inc.(纳斯达克代码：REPL-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
接受Replimune Group Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收Replimune Group和相关公司的最新新闻和分析师评级的每日摘要。